Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Telaprevir to boceprevir switch highlights lack of cross-reactivity.

Literature DB >> 23166191

Telaprevir to boceprevir switch highlights lack of cross-reactivity.

Amanda Carlson¹, Zachery Gregorich, Rob Striker.

Abstract

Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 23166191 PMCID： PMC3732052 DOI： 10.1093/cid/cis960

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

11 in total

1. Diagnosis, management, and treatment of hepatitis C.

Authors: Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal: Hepatology Date: 2004-04 Impact factor: 17.425

Review 2. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Authors: Adeel A Butt; Fasiha Kanwal
Journal: Clin Infect Dis Date: 2011-12-07 Impact factor: 9.079

3. Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors: Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal: N Engl J Med Date: 2011-06-23 Impact factor: 91.245

4. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Authors: Jeremie Guedj; Alan S Perelson
Journal: Hepatology Date: 2011-05-02 Impact factor: 17.425

5. Drug rash with eosinophilia and systemic symptoms due to telaprevir.

Authors: H Montaudié; T Passeron; N Cardot-Leccia; N Sebbag; J P Lacour
Journal: Dermatology Date: 2010-08-25 Impact factor: 5.366

6. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245

7. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Authors: Fumitaka Suzuki; Yoshiyuki Suzuki; Norio Akuta; Hitomi Sezaki; Hiromi Yatsuji; Yasuji Arase; Miharu Hirakawa; Yusuke Kawamura; Tetsuya Hosaka; Masahiro Kobayashi; Satoshi Saito; Kenji Ikeda; Mariko Kobayashi; Sachiyo Watahiki; Rie Mineta; Satomi Iwasaki; Hiromitsu Kumada
Journal: J Clin Virol Date: 2009-10-25 Impact factor: 3.168

8. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Authors: Tara L Kieffer; Christoph Sarrazin; Janice S Miller; Martin W Welker; Nicole Forestier; Hendrik W Reesink; Ann D Kwong; Stefan Zeuzem
Journal: Hepatology Date: 2007-09 Impact factor: 17.425

Review 9. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances?

Authors: Jane Frumin; Jason C Gallagher
Journal: Ann Pharmacother Date: 2009-02-03 Impact factor: 3.154

10. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors: Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal: Hepatology Date: 2011-09-26 Impact factor: 17.425

3 in total

1. Stearoyl coenzyme A desaturase 1 is associated with hepatitis C virus replication complex and regulates viral replication.

Authors: Lam N Nguyen; Yun-Sook Lim; Long V Pham; Hae-Young Shin; Yong-Sun Kim; Soon B Hwang
Journal: J Virol Date: 2014-08-13 Impact factor: 5.103

2. Management algorithm for genotype 1 hepatitis C virus.

Authors: Arthur Y Kim
Journal: F1000Prime Rep Date: 2013-07-01

3. Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.

Authors: Saehong Min; Yun-Sook Lim; Dongjo Shin; Chorong Park; Jae-Bong Park; Seungtaek Kim; Marc P Windisch; Soon B Hwang
Journal: Front Microbiol Date: 2017-06-19 Impact factor: 5.640

3 in total